Skip to content

Randomised controlled trial to evaluate tolerance, intake and safety of a new high-energy high-protein oral nutritional supplement in elderly subjects in need of oral nutritional support.

Randomised controlled trial to evaluate tolerance, intake and safety of a new high-energy high-protein oral nutritional supplement in elderly subjects in need of oral nutritional support.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON26236
Enrollment
68
Registered
2010-10-12
Start date
2010-10-14
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malnutrition Ondervoeding

Interventions

Duration of intervention: 56 days. 1. Intervention group: New high-energy high-protein oral nutritional supplement
2. Control group: Standard high-energy high-protein oral nutritional supplement.

Sponsors

Danone Research - Centre for Specialised Nutrition
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male/female subjects ≥ 65 years of age; 2. Subject is in need of oral nutritional support of ≥ 300 kcal/day; 3. Subject is expected to require oral nutritional support for at least 8 weeks; 4. Subject has given written informed consent; 5. Subject is able to comply with the protocol (e.g. answer questions, collect urine).

Exclusion criteria

Exclusion criteria: 1. Known inflammatory bowel disease (e.g. Crohn's disease); 2. Known lactose intolerance and not using lactase; 3. Known galactosaemia; 4. Known cow's milk allergy; 5. Known major hepatic dysfunction: symptomatic hepatic dysfunction or previous serum transaminase (ALAT, ASAT, or alkaline phosphatase) levels more than 5 times upper limit of normal; 6. Known renal dysfunction: symptomatic renal dysfunction or a previous GFR < 60 mL/min/1.73 m2 for longer than 3 months (stage 3 - stage 5 chronic kidney disease); 7. Requirement of a protein restricted diet (such as for renal failure); 8. Ileostomy or colostomy; 9. Parenteral feeding; 10. Tube feeding; 11. Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements; 12. Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.

Design outcomes

Primary

MeasureTime frame
Tolerance: 1. Daily stool frequency and consistency; 2. Incidence and intensity of gastrointestinal symptoms.

Secondary

MeasureTime frame
Intake and safety.

Contacts

Public ContactMarjolein Vossers

Danone Research - Centre for Specialised Nutrition P.O.Box 7005

marjolein.vossers@danone.com+31 (0)317 467955

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)